PCSK9 and familial hyperaldosteronism: The second case (Table 2; ID:#423), a 45 years old man with LDL-c of 6.8 mmol/L on lipid-lowering treatment (Rosuvastatin 20 mg + Ezetimibe 10 mg) (corrected LDL-c = 18.2 mmol/L), carried a variant in LDLR (p.Asp477Asn) and one in PCSK9 (p.Leu108Arg), both previously reported as FH causal mutations.